ALK and non-small cell lung carcinoma: The phase II CAP-BRAIN trial has revealed an intracranial ORR of 52.5% in treatment-naïve patients with nonsquamous NSCLC without EGFR mutations or ALK translocations and at least three BrMs treated with camrelizumab and carboplatin/pemetrexed [129].